Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02155218 · ClinicalTrials.gov registry record · NA
Improving the Concentration of MR Contrast in the Arteries
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02155218 is a NA study that has completed, run by University of Washington. The registered enrollment target is 26 participants.
The verdict
NCT02155218, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
In Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) a contrast agent is injected into an arm vein using a programmable medical device called a power injector. Once the contrast has circulated to the blood vessel of interest they can be imaged with MRI and distinctly separated from surrounding non-vascular tissue. This project is designed to find the best way to administer the contrast agent during CE-MRA to produce the best images. The clinical availability of programmable power injectors facilitates the use of variable contrast rate and volume injection protocols that are based on patient specific parameters. CE-MRA is a valuable imaging tool for diagnosing abnormalities of the major blood vessels in the chest and abdomen. It is often used in conjunction with cardiac magnetic resonance (CMR) examinations to evaluate the blood vessels of the heart and lung. CE-MRA is attractive because 1) it does not involve radiation, and 2) the contrast agents used are not toxic to the kidneys and can be used in patients who are at greater risk for kidney dysfunction following iodinated contrast agents. We plan to administer a small (1cc) test amount of contrast, taking pictures as the contrast passes through the blood vessels, and analyze the results. Using this information, we will administer an individually patient-tailored injection given in multiple phases (i.e., a "multi-phasic" injection) to maintain constant contrast concentration (and therefore constant signal intensity) throughout the scan. We believe this will reduce image blurring, and improve the sharpness and likely the diagnostic quality of CE-MRA.
Interventions
- OTHER Standard Injection Rate
- OTHER Patient Tailored Injection Rate
- OTHER gadolinium contrast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02155218
The ClinicalTrials.gov registry entry for NCT02155218 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard Injection Rate is the first listed.
NCT02155218 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02155218 about?
NCT02155218 is a clinical study titled "Improving the Concentration of MR Contrast in the Arteries". In Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) a contrast agent is injected into an arm vein using a programmable medical device called a power injector. Once the contrast has circulated to the blood vessel of interest they can be imaged with MRI and distinctly separated from surroundi...
What is the current status of trial NCT02155218?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2014-06. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02155218?
The interventions under investigation include: Standard Injection Rate (OTHER), Patient Tailored Injection Rate (OTHER), gadolinium contrast (OTHER).
Who is sponsoring clinical trial NCT02155218?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.